Latest Tenofovir Stories
NEW ORLEANS, and RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2010 /PRNewswire/ -- Scientists from Chimerix, Inc.
BURLINGTON, Mass., Oct.
Higher clinical drop-out rates among women are a concern when testing for effectiveness of HIV treatments.
A new landmark study, which demonstrated it is possible to recruit large numbers of women into a clinical trial evaluating treatments for HIV infection, found no significant gender-based differences in response to the anti-HIV drugs darunavir and ritonavir â€” at least among those who remained in the trial to the end.
NEW YORK, Sept.
RESEARCH TRIANGLE PARK, N.C., July 28 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate...
TITUSVILLE, N.J., July 26 /PRNewswire/ -- Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S.
VIENNA, July 22 /PRNewswire/ -- Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.
CAPRISA 004 trial shows moderate protection against transmission of virus JOHANNESBURG and WASHINGTON, July 19 /PRNewswire-USNewswire/ -- Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria.
WASHINGTON, July 19 /PRNewswire-USNewswire/ -- USAID Administrator Rajiv Shah released the following statement on today's historic CAPRISA 004 trial results: (Logo: http://photos.prnewswire.com/prnh/20091022/USAIDLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20091022/USAIDLOGO) USAID is proud to be the major funder of the first-ever proof of concept that a microbicide can effectively and safely reduce the transmission of HIV from men to vulnerable women.
- To give a box on the ear to.